Hepatitis B and liver transplantation.
Liver transplantation is the treatment of choice for patients with liver failure secondary to chronic hepatitis B. However, liver transplantation is complicated by the risk of recurrent hepatitis B virus infection, which significantly impairs graft and patient survival. The main risk factor for the development of recurrent hepatitis B virus infection is the virus load at the time of transplantation. The development of antiviral medications, such as lamivudine and adefovir, and the implementation of effective prophylactic regimens using hepatitis B immune globulin have significantly improved the outcomes of hepatitis B after liver transplantation. However, current approaches continue to be hampered by the extremely high cost of treatment and the emergence of drug-resistant viral mutations. Ongoing studies are necessary to establish the most cost-effective approaches to prevent recurrent hepatitis B virus infection after liver transplantation.
Tung
Bruce Y
BY
Division of Gastroenterology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Kowdley
Kris V
KV
D000998:Antiviral Agents / Q000627:therapeutic use; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D017093:Liver Failure / Q000209:etiology* / Q000601:surgery*; D016031:Liver Transplantation; D012008:Recurrence; D012307:Risk Factors
D000998:Antiviral Agents